Vaxcyte SVP surrenders shares for RSU taxes

Vaxcyte, Inc. SVP, Finance Elvia Cowan reported tax-withholding dispositions of a total of 567 shares of Common Stock on September 2, 2025, at $31.56 per share, surrendered to the issuer to cover tax obligations from RSU vesting.

Rhea-AI Filing Summary

Vaxcyte, Inc. SVP, Finance Elvia Cowan reported tax-withholding dispositions of a total of 567 shares of Common Stock on September 2, 2025, at $31.56 per share, surrendered to the issuer to cover tax obligations from RSU vesting. After these transactions, Cowan directly holds 26,638 shares of Common Stock.

Insights

Securities Analyst

TL;DR: Officer surrendered vested RSU shares to cover taxes; routine, limited market impact.

These transactions are typical tax-withholding dispositions following RSU vesting rather than open-market sales for liquidity. The per-share price of $31.56 reflects the valuation at disposal. The remaining beneficial ownership reported on each line indicates continued equity exposure by the officer. For investors, such filings primarily signal routine compensation settlement and not a change in corporate control or a significant shift in insider conviction.

Corporate Governance Expert

TL;DR: Transactions are administrative tax withholdings; compliance with disclosure requirements is evident.

The Form 4 discloses that shares were surrendered to satisfy tax withholding on vested RSUs, a standard corporate practice. The filing was executed by an attorney-in-fact and reports post-transaction beneficial ownership counts, aligning with Section 16 reporting rules. No indications of atypical timing, volumes, or coded transactions that would suggest governance concerns.

Insider Trade Summary

Exercise Price or Tax Liability: 567 shares

Exercise Price or Tax Liability 2 txns

Insider Cowan Elvia

Role SVP, FINANCE

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	242	$31.56	$8K
Exercise Price or Tax Liability	Common Stock	325	$31.56	$10K

Holdings After Transaction: Common Stock — 26,638 shares (Direct)

Footnotes (1)

1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Key Figures

Tax-withholding shares (total): 567 shares First tax-withholding transaction: 242 shares Second tax-withholding transaction: 325 shares +2 more

5 metrics

Tax-withholding shares (total) 567 shares Total shares surrendered to issuer to cover RSU-related tax obligations

First tax-withholding transaction 242 shares Common Stock surrendered on 2025-09-02 for tax withholding

Second tax-withholding transaction 325 shares Common Stock surrendered on 2025-09-02 for tax withholding

Price per share used for tax withholding $31.5600 per share Applied to both Form 4 tax-withholding dispositions

Post-transaction holdings 26,638 shares Direct Common Stock ownership by Elvia Cowan after reported transactions

Key Terms

RSUs, tax withholding obligations, surrendered to the Issuer

3 terms

RSUs financial

"upon the vesting of RSUs."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax withholding obligations financial

"to cover applicable tax withholding obligations realized upon the vesting"

surrendered to the Issuer financial

"Represents shares surrendered to the Issuer to cover applicable tax"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaxcyte (PCVX) insider Elvia Cowan report in this Form 4?

Elvia Cowan reported tax-withholding dispositions of 567 shares of Vaxcyte Common Stock on September 2, 2025, at $31.56 per share, surrendered to the issuer to cover RSU-related tax obligations, and now directly holds 26,638 shares.

How many Vaxcyte (PCVX) shares were surrendered for tax withholding?

Cowan surrendered a total of 567 shares of Vaxcyte Common Stock, in two transactions of 242 and 325 shares, to cover applicable tax withholding obligations realized upon the vesting of RSUs.

What is Elvia Cowan’s remaining Vaxcyte (PCVX) shareholding after these transactions?

After the reported tax-withholding dispositions, Elvia Cowan directly holds 26,638 shares of Vaxcyte Common Stock, as the post-transaction canonical holding disclosed in the filing’s position information.

Were the Vaxcyte (PCVX) Form 4 transactions open-market sales?

No. Both transactions are coded F, indicating shares were delivered to the issuer to satisfy tax obligations. The footnote states the shares were surrendered to cover tax withholding upon the vesting of RSUs, not sold on the open market.

At what price were Vaxcyte (PCVX) shares valued for Cowan’s tax-withholding dispositions?

Each of the reported tax-withholding dispositions used a price of $31.56 per share, applied to both the 242-share and 325-share transactions when determining the value of shares surrendered to cover RSU-related tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 04:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		F		242(1)	D	$31.56	26,963	D
Common Stock	09/02/2025		F		325(1)	D	$31.56	26,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.